Lumosa Therapeutics Co., Ltd. received notification today (2023/9/26) from partner, AMed Co., Ltd. (AMed) that its LT1001, an extended-release analgesic injection (Naldebain(R)), has received import approval from Brunei. Naldebain has received approvals in Taiwan, Singapore, Thailand, Malaysia, and Ukraine, demonstrating a robust international certification process. Lumosa and AMed have signed an exclusive licensing agreement covering ten Southeast Asian countries, covering drug licensing applications, market development, and sales. This agreement continues to advance regional expansion and strengthen global competitiveness in the pain management field.